ArticleJournal of clinical laboratory analysis2026
Clinical Interpretation of Platelet Activation Marker sCLEC-2 in Antiphospholipid Syndrome.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Soluble CLEC-2 as an Emerging Biomarker of In Vivo Platelet Activation.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoluble C-type lectin-like receptor 2 (sCLEC-2) has emerged as a biomarker of platelet activation and thrombus formation. Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and pregnancy complications, driven in part by platelet activation. However, the clinical utility of sCLEC-2 and the sCLEC-2/D-dimer ratio in APS remains unclear.
methodsPlasma samples from 19 patients with primary APS, 30 with SLE-associated APS, 10 with SLE without APS, 40 with other collagen diseases, and 40 healthy controls (n = 139) were analyzed. Plasma sCLEC-2 levels and D-dimer levels were quantified by immunoassay. Antiphospholipid antibodies (anti-cardiolipin antibodies and anti-β
resultsUsing the upper limit of the 95% CI of healthy controls as a cutoff, sCLEC-2 positivity was observed in 100% of non-APS autoimmune disease patients, and 98.0% of APS patients. sCLEC-2, D-dimer, and the sCLEC-2/D-dimer ratio were significantly higher in non-APS and APS groups compared with controls (p < 0.001). A slight but significant difference in the sCLEC-2 and the ratio was observed between the non-APS and APS groups. However, no significant differences were found among APS subgroups stratified by thrombosis type. sCLEC-2 showed no correlation with any of four major antiphospholipid antibody titers.
conclusionAlthough we observed raised sCLEC-2 and sCLEC-2/D-dimer ratio among APS and non-APS groups and modest differences between the two groups, clinical interpretation of the findings requires a prospective study evaluating dynamic changes of sCLEC-2 in the clinical course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.